Pharmaceutical major Johnson & Johnson (NYSE: JNJ) reported stronger-than-expected results for the second quarter. The solid results were on the back of both revenue and earnings surpassing estimates. Revenue, Earnings Up Johnson & Johnson reported quarterly revenues of $24 billion which denotes a growth of 3% from the previous year. Moreover, the figure surpassed the consensus estimate of $23.77 billion. Year-over-year growth of 6.7% and 3% in pharmaceutical revenues and worldwide revenues, respectively, drove the overall growth in revenues for the company. The company’s earnings per share (EPS) for the quarter came in at $2.59, a 4.4% increase from the prior year.
https://www.tipranks.com/news/johnson-johnson-second-quarter-results-impress?utm_source=advfn.com&utm_medium=referral
Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Ago 2022 até Set 2022 Click aqui para mais gráficos Johnson and Johnson.
Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Set 2021 até Set 2022 Click aqui para mais gráficos Johnson and Johnson.